Nanobody-Drug Conjugates: Redefining Precision in Bispecific ADC Design
- Exploring how conventional ADCs suffer from fixed architectures, limiting tumor selectivity and pharmacokinetic control, resulting in off-target toxicity
- Outlining bispecific nanobody-drug conjugates targeting an IO receptor, combined with HSA and a chemotherapeutic, enable simultaneous immune checkpoint engagement and tumor killing
- Explaining how this bispecific design overcomes resistance and systemic toxicity, enhancing drug exposure, pharmacokinetic stability, and safety